Associations Between Systemic Markers of Bone Turnover or Bone Mineral Density and Anti-Resorptive Agent-Related Osteonecrosis of the Jaw in Patients Treated with Anti-Resorptive Agents

Overview

Journal Yonago Acta Med

Specialty General Medicine

Date 2016 Apr 6

PMID 27046950

Authors

Kazuhito Tohashi

Motoki Nakabayashi

Isamu Kodani

Kazunori Kidani

Kazuo Ryoke

Affiliations

Soon will be listed here.

Abstract

Background: Some previous studies have examined anti-resorptive agent-related osteonecrosis of the jaw (ARONJ) prediction using systemic markers of bone turnover as risk factors. Radiographic imaging is also effective at detecting ARONJ. In this study, computed tomography (CT)-derived bone mineral density (BMD) values and the levels of systemic markers of bone turnover were evaluated, and then each parameter was compared between patients that developed ARONJ and those who did not after treatment with systemic anti-resorptive agents. The aim of this study was to determine whether systemic markers of bone turnover and/or BMD values can be used to predict the risk of ARONJ.

Methods: The subjects' serum levels of cross-linked N-terminal telopeptide of type I collagen (NTX) and bone alkaline phosphatase (BAP) (systemic markers of bone turnover) were measured. BMD was calibrated to CT values using a medical imaging phantom. Then, the subjects' BMD were assessed using quantitative computed tomography. Fifty-six patients who had received systemic anti-resorptive agents were included in this study. Thirty-two of the patients developed ARONJ after receiving the drugs whereas the remaining 24 did not.

Results: No correlation was observed between the serum levels of the systemic markers of bone turnover and the incidence of ARONJ. On the other hand, the ARONJ patients exhibited higher mandibular BMD values than the control group. BMD was not associated with healing or the clinical stage of ARONJ.

Conclusion: These results suggest that increased mandibular BMD values are associated with ARONJ. Furthermore, mandibular BMD might serve as a novel marker for predicting the risk of ARONJ in patients that are taking anti-resorptive agents and are about to undergo tooth extraction. Accordingly, mandibular BMD could be a useful tool for aiding risk assessments and guiding treatment decisions.

References

Rocha G, Jaguar G, Moreira C, Neves E, Fonseca F, Pedreira E . Radiographic evaluation of maxillofacial region in oncology patients treated with bisphosphonates. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012; 114(5 Suppl):S19-25. DOI: 10.1016/j.tripleo.2011.08.016. View

Berenson J, Hillner B, Kyle R, Anderson K, Lipton A, Yee G . American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2002; 20(17):3719-36. DOI: 10.1200/JCO.2002.06.037. View

Rosen L, Gordon D, Tchekmedyian N, Yanagihara R, Hirsh V, Krzakowski M . Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer. 2004; 100(12):2613-21. DOI: 10.1002/cncr.20308. View

Stockmann P, Hinkmann F, Lell M, Fenner M, Vairaktaris E, Neukam F . Panoramic radiograph, computed tomography or magnetic resonance imaging. Which imaging technique should be preferred in bisphosphonate-associated osteonecrosis of the jaw? A prospective clinical study. Clin Oral Investig. 2009; 14(3):311-7. DOI: 10.1007/s00784-009-0293-1. View

Purcell P, Boyd I . Bisphosphonates and osteonecrosis of the jaw. Med J Aust. 2005; 182(8):417-8. DOI: 10.5694/j.1326-5377.2005.tb06762.x. View

Sinningen K, Tsourdi E, Rauner M, Rachner T, Hamann C, Hofbauer L . Skeletal and extraskeletal actions of denosumab. Endocrine. 2012; 42(1):52-62. DOI: 10.1007/s12020-012-9696-x. View

Ruggiero S, Fantasia J, Carlson E . Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006; 102(4):433-41. DOI: 10.1016/j.tripleo.2006.06.004. View

Hamada H, Matsuo A, Koizumi T, Satomi T, Chikazu D . A simple evaluation method for early detection of bisphosphonate-related osteonecrosis of the mandible using computed tomography. J Craniomaxillofac Surg. 2014; 42(6):924-9. DOI: 10.1016/j.jcms.2014.01.012. View

ORyan F, Khoury S, Liao W, Han M, Hui R, Baer D . Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator. J Oral Maxillofac Surg. 2009; 67(7):1363-72. DOI: 10.1016/j.joms.2009.03.005. View

10.

Migliorati C, Schubert M, Peterson D, Seneda L . Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer. 2005; 104(1):83-93. DOI: 10.1002/cncr.21130. View

11.

Bagan J, Jimenez Y, Murillo J, Hernandez S, Poveda R, Sanchis J . Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases. Oral Oncol. 2005; 42(3):327-9. DOI: 10.1016/j.oraloncology.2005.08.001. View

12.

Khosla S, Burr D, Cauley J, Dempster D, Ebeling P, Felsenberg D . Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007; 22(10):1479-91. DOI: 10.1359/jbmr.0707onj. View

13.

Nussbaum S, Younger J, Vandepol C, Gagel R, Zubler M, Chapman R . Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Am J Med. 1993; 95(3):297-304. DOI: 10.1016/0002-9343(93)90282-t. View

14.

Bravenboer N, Papapoulos S, Holzmann P, Hamdy N, Netelenbos J, Lips P . Bone histomorphometric evaluation of pamidronate treatment in clinically manifest osteoporosis. Osteoporos Int. 2000; 9(6):489-93. DOI: 10.1007/s001980050175. View

15.

Treister N, Friedland B, Woo S . Use of cone-beam computerized tomography for evaluation of bisphosphonate-associated osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010; 109(5):753-64. DOI: 10.1016/j.tripleo.2009.12.005. View

16.

Walter C, Laux C, Sagheb K . Radiologic bone loss in patients with bisphosphonate-associated osteonecrosis of the jaws: a case-control study. Clin Oral Investig. 2013; 18(2):385-90. DOI: 10.1007/s00784-013-0974-7. View

17.

Lipton A, Fizazi K, Stopeck A, Henry D, Brown J, Yardley D . Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012; 48(16):3082-92. DOI: 10.1016/j.ejca.2012.08.002. View

18.

Sonis S, Watkins B, Lyng G, Lerman M, Anderson K . Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. Oral Oncol. 2008; 45(2):164-72. DOI: 10.1016/j.oraloncology.2008.04.013. View

19.

Mortensen M, Lawson W, Montazem A . Osteonecrosis of the jaw associated with bisphosphonate use: Presentation of seven cases and literature review. Laryngoscope. 2007; 117(1):30-4. DOI: 10.1097/01.mlg.0000240885.64568.9e. View

20.

Walter C, Al-Nawas B, Grotz K, Thomas C, Thuroff J, Zinser V . Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol. 2008; 54(5):1066-72. DOI: 10.1016/j.eururo.2008.06.070. View